ATAI has raised $100 million to turn psychedelics into treatments for depression and anxiety. Now the unusual biotech is gearing up to raise millions more for the next phase of human testing.

Business Insider

27 Feb 2020 0 shares 1 views

ATAI has raised $100 million to turn psychedelics into treatments for depression and anxiety. Now the unusual biotech is gearing up to raise millions more for the next phase of human testing.

Business Insider

Published 27 Feb 2020

· Florian Brand helped start ATAI Life Sciences with one vision in mind: to effectively treat mental-health disorders by turning psychedelics into medicines.
· The way to do that? By bringing psychedelics through clinical trials and getting approval from regulatory agencies.
· Prominent backers like Mike Novogratz, Peter...

Full Article

ATAI has raised $100 million to turn psychedelics into treatments for depression and anxiety. Now the unusual biotech is gearing up to raise millions more for the next phase of human testing.

ATAI has raised $100 million to turn psychedelics into treatments for depression and anxiety. Now the unusual biotech is gearing up to raise millions more for the next phase of human testing.

You might like